Phase Ib Study of PDR001 in Combination With Regorafenib in Adult Patients With Previously Treated Metastatic Microsatellite Stable (MSS) Colorectal Cancer

Next Previous
Trial Profile

Phase Ib Study of PDR001 in Combination With Regorafenib in Adult Patients With Previously Treated Metastatic Microsatellite Stable (MSS) Colorectal Cancer

Recruiting
Phase of Trial: Phase I

Latest Information Update: 04 Apr 2018

At a glance

  • Drugs Spartalizumab (Primary) ; Regorafenib
  • Indications Adenocarcinoma; Colorectal cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Novartis Pharmaceuticals

    • Most Recent Events

    • 19 Feb 2018 Planned End Date changed from 11 Nov 2019 to 31 Aug 2018.
    • 19 Feb 2018 Planned primary completion date changed from 11 Nov 2019 to 31 Aug 2018.
    • 20 Jun 2017 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top